目的:探讨秦皮甲素对人结直肠癌SW480细胞迁移和侵袭能力的影响,并研究其具体的分子机制.方法:以人结直肠癌SW480细胞作为研究对象,采用细胞划痕和Transwell实验检测细胞迁移和侵袭能力,采用shRNA干扰技术使SW480细胞中人类免疫缺陷病...目的:探讨秦皮甲素对人结直肠癌SW480细胞迁移和侵袭能力的影响,并研究其具体的分子机制.方法:以人结直肠癌SW480细胞作为研究对象,采用细胞划痕和Transwell实验检测细胞迁移和侵袭能力,采用shRNA干扰技术使SW480细胞中人类免疫缺陷病毒短转录诱导物连接因子-1(factor that binds to indeucer of short transcripts-1,FBI-1)基因的沉默,利用Western blot法检测波形蛋白(Vimentin)、E-钙黏蛋白(E-cadherin)和FBI-1等蛋白的表达变化.结果:该药物秦皮甲素可使人结直肠癌SW480细胞愈合能力、迁移和侵袭能力均显著下降,同时下调Vimentin和FBI-1蛋白表达水平以及上调E-cadherin蛋白表达水平,上述作用具有浓度依赖性.但经shRNA沉默FBI-1基因表达后,该蛋白的表达水平显著下降;同时FBI-1干扰SW480细胞中E-cadherin蛋白表达水平显著升高,Vimentin蛋白表达水平均显著下降,同时细胞迁移和侵袭能力也降低.结论:秦皮甲素具有浓度依赖性地抑制人结直肠癌SW480细胞迁移和侵袭能力,这可能与秦皮甲素抑制FBI-1蛋白表达,继而下调Vimentin蛋白表达和上调E-cadherin蛋白表达有关.展开更多
Gastrointestinal(GI)cancers represent the leading cause of cancer-related mortality worldwide.Antibody drug conjugates(ADCs)are a rapidly growing new class of anti-cancer agents which may improve GI cancer patient sur...Gastrointestinal(GI)cancers represent the leading cause of cancer-related mortality worldwide.Antibody drug conjugates(ADCs)are a rapidly growing new class of anti-cancer agents which may improve GI cancer patient survival.ADCs combine tumour-antigen specific antibodies with cytotoxic drugs to deliver tumour cell specific chemotherapy.Currently,only two ADCs[brentuximab vedotin and trastuzumab emtansine(T-DM1)]have been Food and Drug Administration approved for the treatment of lymphoma and metastatic breast cancer,respectively.Clinical research evaluating ADCs in GI cancers has shown limited success.In this review,we will retrace the relevant clinical trials investigating ADCs in GI cancers,especially ADCs targeting human epidermal growth receptor 2,mesothelin,guanylyl cyclase C,carcinogenic antigen-related cell adhesion molecule 5(also known as CEACAM5)and other GI malignancy specific targets.We will review potential hurdles for their success and provide new perspective for future treatment.展开更多
文摘目的:探讨秦皮甲素对人结直肠癌SW480细胞迁移和侵袭能力的影响,并研究其具体的分子机制.方法:以人结直肠癌SW480细胞作为研究对象,采用细胞划痕和Transwell实验检测细胞迁移和侵袭能力,采用shRNA干扰技术使SW480细胞中人类免疫缺陷病毒短转录诱导物连接因子-1(factor that binds to indeucer of short transcripts-1,FBI-1)基因的沉默,利用Western blot法检测波形蛋白(Vimentin)、E-钙黏蛋白(E-cadherin)和FBI-1等蛋白的表达变化.结果:该药物秦皮甲素可使人结直肠癌SW480细胞愈合能力、迁移和侵袭能力均显著下降,同时下调Vimentin和FBI-1蛋白表达水平以及上调E-cadherin蛋白表达水平,上述作用具有浓度依赖性.但经shRNA沉默FBI-1基因表达后,该蛋白的表达水平显著下降;同时FBI-1干扰SW480细胞中E-cadherin蛋白表达水平显著升高,Vimentin蛋白表达水平均显著下降,同时细胞迁移和侵袭能力也降低.结论:秦皮甲素具有浓度依赖性地抑制人结直肠癌SW480细胞迁移和侵袭能力,这可能与秦皮甲素抑制FBI-1蛋白表达,继而下调Vimentin蛋白表达和上调E-cadherin蛋白表达有关.
文摘Gastrointestinal(GI)cancers represent the leading cause of cancer-related mortality worldwide.Antibody drug conjugates(ADCs)are a rapidly growing new class of anti-cancer agents which may improve GI cancer patient survival.ADCs combine tumour-antigen specific antibodies with cytotoxic drugs to deliver tumour cell specific chemotherapy.Currently,only two ADCs[brentuximab vedotin and trastuzumab emtansine(T-DM1)]have been Food and Drug Administration approved for the treatment of lymphoma and metastatic breast cancer,respectively.Clinical research evaluating ADCs in GI cancers has shown limited success.In this review,we will retrace the relevant clinical trials investigating ADCs in GI cancers,especially ADCs targeting human epidermal growth receptor 2,mesothelin,guanylyl cyclase C,carcinogenic antigen-related cell adhesion molecule 5(also known as CEACAM5)and other GI malignancy specific targets.We will review potential hurdles for their success and provide new perspective for future treatment.
